How Tirzepatide Works for Weight Loss
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight.
- Clinical trials demonstrated up to 20.9% average body weight loss at 15 mg over 72 weeks (SURMOUNT-1).
- In December 2024, Zepbound received FDA approval as the first medication ever indicated for moderate-to-severe obstructive sleep apnea in adults with obesity.
- Common side effects are gastrointestinal — nausea, diarrhea, vomiting — and are generally mild to moderate, most pronounced during dose escalation.
- Tirzepatide is administered via weekly subcutaneous injection, with gradual dose escalation from 2.5 mg to a maximum of 15 mg.
Introduction
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the active ingredient in both Zepbound (weight management) and Mounjaro (type 2 diabetes). It activates receptors for two naturally occurring hormones that regulate appetite, food intake, and blood sugar. By mimicking both GIP and GLP-1, tirzepatide reduces appetite and caloric intake in a way that single-pathway GLP-1 agonists like semaglutide do not.
The mechanism of action of tirzepatide is distinct from older weight loss medications. Unlike traditional appetite suppressants that primarily target the central nervous system, tirzepatide works peripherally by interacting with GIP and GLP-1 receptors in the gut and other tissues involved in appetite regulation and metabolic function. This dual agonist approach produces both the appetite suppression associated with GLP-1 activation and additional metabolic benefits associated with GIP receptor activation.
FDA-Approved Uses
As of 2026, tirzepatide (Zepbound) carries two FDA-approved indications:
- Chronic weight management — approved November 2023 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol. Intended for use alongside a reduced-calorie diet and increased physical activity. Learn more about Zepbound at Rivas →
- Moderate-to-severe obstructive sleep apnea (OSA) — approved December 2024, making Zepbound the first medication ever FDA-approved specifically for OSA. Indicated for adults with moderate-to-severe OSA and obesity.
Mounjaro (tirzepatide) remains separately indicated for glycemic control in adults with type 2 diabetes, including for pediatric patients aged 10 and older as of recent labeling updates.
Clinical Trials and Efficacy
SURMOUNT Trials — Weight Management
The SURMOUNT program evaluated tirzepatide across multiple populations for chronic weight management, enrolling more than 5,000 participants across six registration studies.
SURMOUNT-1 investigated tirzepatide in adults without diabetes. At 15 mg once weekly over 72 weeks, participants lost an average of 20.9% of body weight compared to 3.1% in the placebo group. The average starting weight was 231 pounds (BMI 38 kg/m²). This equates to a mean reduction of approximately 48 pounds, bringing average weight from 231 to about 183 pounds. Results were published in the New England Journal of Medicine.
SURMOUNT-2 focused on adults with obesity or overweight and type 2 diabetes. Participants taking 15 mg lost an average of 15.7% of body weight over 72 weeks, compared to 3.3% for placebo — accompanied by meaningful improvements in glycemic control.
Both trials showed reductions in blood pressure, lipid levels, and fasting insulin alongside weight loss. Self-reported physical function and quality of life also improved.
SURPASS Trials — Type 2 Diabetes
The SURPASS trials evaluated tirzepatide’s efficacy in glycemic control. Across multiple studies, tirzepatide produced superior HbA1c reductions compared to insulin, sulfonylureas, and other GLP-1 receptor agonists, with HbA1c decreases of up to 2.4%. Importantly, these improvements occurred alongside significant weight loss — in contrast to insulin therapy, which is associated with weight gain.
SURMOUNT-OSA — Obstructive Sleep Apnea
In two phase 3 trials enrolling 469 adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea index (AHI) by approximately 25 events per hour versus 5 events per hour with placebo — about five times the effect of placebo. Nearly half of trial participants achieved such improvement that they no longer had symptoms associated with OSA. These results, published in the New England Journal of Medicine, formed the basis for FDA approval in December 2024.
Participants also lost an average of 18–20% of body weight over 52 weeks. Zepbound is the first medication ever approved for OSA — prior to this approval, treatment relied entirely on CPAP devices, oral appliances, and surgery.
Safety and Side Effects
Common Side Effects
Tirzepatide’s most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion. These are generally mild to moderate and most pronounced during dose escalation, with many patients reporting improvement as the body adjusts. Gradual dose escalation — the standard protocol — is specifically designed to reduce GI side effects and improve long-term tolerability.
At Rivas, providers monitor patients at every visit during escalation. If a patient is experiencing significant side effects, the dose can be held or reduced rather than stopping treatment entirely.
Warnings and Precautions
Tirzepatide carries an FDA black box warning regarding the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), observed in rodent studies. The clinical relevance in humans is unknown, but tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should report any neck lump, hoarseness, difficulty swallowing, or shortness of breath.
Other considerations requiring monitoring include: pancreatitis, gallbladder problems (cholelithiasis), hypoglycemia when used with insulin or sulfonylureas, acute kidney injury, and diabetic retinopathy in patients with type 2 diabetes. Serious allergic reactions are rare but possible.
Cardiovascular Safety
The SURMOUNT-MMO trial — a dedicated cardiovascular outcomes trial for tirzepatide in adults with obesity — is ongoing. Completed semaglutide cardiovascular outcomes data (SELECT trial, published 2023) demonstrated a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease. While tirzepatide shares a mechanistic class, its specific cardiovascular outcomes data from SURMOUNT-MMO are anticipated and will provide more definitive guidance. The weight loss, blood pressure reductions, and lipid improvements observed in the SURMOUNT trials are broadly consistent with favorable cardiovascular trends.
Long-Term Considerations
As with all GLP-1 class medications, the clinical understanding of tirzepatide’s long-term safety profile continues to evolve. Ongoing monitoring for effects on thyroid, liver, kidneys, and endocrine systems remains standard of care. The data available to date — across thousands of patients in controlled trials and growing real-world use — support a generally favorable safety profile consistent with the GLP-1 class.
Dosing and Administration
Dosage Schedule
Tirzepatide is administered by subcutaneous injection once weekly. The starting dose is 2.5 mg, escalated gradually to minimize GI side effects. The standard titration schedule is:
- Weeks 1–4: 2.5 mg
- Weeks 5–8: 5 mg
- Weeks 9–12: 7.5 mg
- Weeks 13–16: 10 mg
- Weeks 17–20: 12.5 mg
- Week 21 onward: 15 mg (maximum dose)
Not all patients need to reach 15 mg. Clinical trial data show significant weight loss at 5 mg, 10 mg, and 12.5 mg, and many patients find their effective maintenance dose well before the maximum. At Rivas, dose decisions are individualized — some patients maintain at lower doses due to excellent response, tolerability preferences, or clinical judgment. Dose escalation is a tool, not a requirement. Use the interactive tirzepatide dosage chart to see the full week-by-week escalation schedule and convert doses to injection units.
Patients experiencing intolerable side effects at any stage can have their dose held or reduced. Slower escalation schedules are used when clinically appropriate.
Administration
Zepbound and Mounjaro are available as single-dose injection pens and as KwikPens. Injections are subcutaneous — into the abdomen, thigh, or upper arm. Patients can self-inject after training, though at Rivas the injection is typically administered in-office by a provider at each visit. If you are using a brand-name KwikPen and need to calculate a fractional dose by counting clicks, see our GLP-1 pen click calculator. For clinical context on why vial-based delivery allows more precise precision dose titration than pen devices, see our microdosing guide.
Drug Interactions
Patients taking insulin or sulfonylureas should be closely monitored for hypoglycemia when starting tirzepatide or adjusting the dose. Dose adjustments of those medications may be needed. Because GLP-1 medications slow gastric emptying, they can affect the absorption of orally administered drugs — particularly those with narrow therapeutic indices. Patients on oral hormonal contraceptives should use a non-oral backup method for 4 weeks after initiation and after each dose escalation.
Tirzepatide at Rivas
Rivas Medical Weight Loss offers both brand-name tirzepatide (Zepbound) and compounded tirzepatide programs across 15 clinic locations in Maryland and Virginia. See current pricing →
At every visit, your provider reviews your weight progress, side effect profile, and overall response — and adjusts your dose accordingly. Because Rivas uses a vial-based delivery model for compounded medications, any dose increment is possible, not just the preset amounts available in brand-name pen devices. This gives providers the clinical flexibility to increase, hold, or reduce dose based on your actual week-to-week response.
Most patients are seen weekly early in treatment, particularly during dose escalation, with visit frequency adjusting as the treatment plan stabilizes.
Frequently Asked Questions
In the SURMOUNT-1 trial, participants at the 15 mg dose lost an average of 20.9% of body weight over 72 weeks. Individual results vary significantly based on starting weight, dose achieved, diet, activity, and metabolic factors. Many patients see meaningful weight loss at doses well below 15 mg.
Most patients notice appetite suppression within the first one to two weeks. Meaningful weight loss typically becomes apparent by weeks four to eight. The full effect of any given dose develops over several weeks, which is why the escalation schedule pauses at each dose level before increasing.
Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management and obstructive sleep apnea. The medications are identical — the difference is the indication, labeling, and in some cases insurance coverage pathways.
No. Compounded tirzepatide is not an FDA-approved product and has not undergone the same clinical review, manufacturing oversight, or efficacy trials as brand-name medications. Compounded versions are prepared by licensed pharmacies and may be appropriate for some patients — a decision made with your provider. Learn about compounded tirzepatide at Rivas →
Yes. In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication ever indicated for moderate-to-severe obstructive sleep apnea in adults with obesity. In clinical trials, tirzepatide reduced breathing disruptions approximately five times more than placebo, and nearly half of participants saw symptoms improve to the point of disease remission.
Weight regain after stopping GLP-1 therapy is well-documented. The body’s weight-regulatory mechanisms tend to drive appetite back toward baseline when the medication is discontinued — consistent with the understanding of obesity as a chronic metabolic condition requiring ongoing management. Decisions about stopping or transitioning off tirzepatide should be made with your provider.
Ready to start tirzepatide at Rivas?
Your provider evaluates whether tirzepatide is right for you, determines your starting dose, draws it from a vial, and administers it in-office — all at your first visit.
Book Your First Visit →From $165/week · Medication included · 15 locations in MD & VA
Learn about all Rivas tirzepatide programs →
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626.
- Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–1205.
- FDA. Zepbound (tirzepatide) Prescribing Information. Revised 2024. accessdata.fda.gov.
- FDA Press Release. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024.
This article is for educational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. All treatment decisions at Rivas are made by a licensed provider following an individualized medical evaluation. Individual results vary.
